Skip to main navigation Skip to search Skip to main content

Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Mortality associated with cannabis used for treatment of epilepsy is not well documented. We discuss two fatalities in the setting of epilepsy and self-determined therapy with cannabis (SDTC). One patient had probable sudden unexpected death in epilepsy, the second death was due to seizure-associated drowning. Both directed SDTC over conventional anti-seizure medications. Where recreational cannabis is legal, decisions to use cannabis are often self-directed and independent of physician advice of cannabis risks, in part because physicians may not be aware of the risk of SDTC. Further study of morbidity and mortality of SDTC in patients with epilepsy is needed.

Original languageEnglish
Pages (from-to)52-53
Number of pages2
JournalEpilepsy and Behavior Case Reports
Volume11
DOIs
StatePublished - Jan 1 2019

Keywords

  • Cannabidiol
  • Marijuana
  • Sudden unexplained death in epilepsy
  • Tetrahydrocannabinol
  • Therapy

Fingerprint

Dive into the research topics of 'Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?'. Together they form a unique fingerprint.

Cite this